Jsp Pharmaceutical Manufacturing (thailand) Public Company Limited · SET:JSP
Jsp Pharmaceutical Manufacturing (thailand) Public — FY2024 Earnings Presentation
26 slides from Jsp Pharmaceutical Manufacturing (thailand) Public's earnings presentation, 2025
Slide 1: Opportunity Day Presentation YE/2024
JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited OPPORTUNITY DAY PRESENTATION YE/2024
Slide 2: YE/2024 Key Highlights
YE/2024 KEY HIGHLIGHTS OUTSTANDING PERFORMANCE Operating Revenue +43.2% YoY 824.5 575.6 YE/2023 YE/2024 Strong Growth of JSP captures “Kidney ‘Medis’ Occupies Key Profit From Operation Suphap Osot Patient” Strategic Areas +9,971.6% YoY ✓ JSP has achieved ✓ JSP supply of kidney- ✓ In 2024, the Compan
Slide 3: Agenda
AGENDA COMPANY OVERVIEW & STRATEGY KEY FINANCIAL PERFORMANCE 2025 OUTLOOK 3
Slide 4: JSP Revenue Breakdown and Business Nature
JSP Revenue Breakdown and Business Nature YE/2024 Revenue Breakdown by Business Line Trading & Others Own Brand • Producing medicine and other Hemodialysis 5% supplement under JSP’s own brand 17% 824.5 41% MB OEM • Providing OEM end to end services for YE/2024 Own Brand customer ✓ R&D 37% ✓ Producti
Slide 5: JSP Invests to Create Synergy Along the Supply Chain
JSP Invests to Create Synergy Along the Supply Chain JSP strengthens its presence across the value chain, positioning itself at the forefront of the industry while continuing to expand its customer base R&D Distribution Kidney Patients 1. Think Tank 2. Manufacturing 3. Distribution 4. Service 5. End
Slide 6: JSP Strategic Directions
JSP Strategic Directions JSP strengthens its presence across the value chain, positioning itself at the forefront of the industry while continuing to expand its customer base 2027 Thailand’s Leading Innovative Pharmaceutical and Supplement Brand 2025 ✓ Ensuring Growth of Operating Capacity Leading P
Slide 7: 2025 Strategy
2025 STRATEGY CORE BUSINESS 1 Elevate Own-Brand 4 Business Expansion • Obtain new product licenses Along the Value Chain • Introduce differentiated • Strengthening Hemodialysis products Business • Launch wide-scale • Trading of medical devices marketing to strengthen • Strengthening Ser vices - bran
Slide 8: Driving Our Core Business
DRIVING OUR CORE BUSINESS Target Target 42% OWN BRAND REVENUE TARGET 39% OEM REVENUE TARGET of total revenue of total revenue U n i t : M i l l i o n Ba h t U n i t : M i l l i o n Ba h t 308.4 337.2 288.5 OEM 192.7 Own Brand 2023 2024F 2025F 2027F 2023 2024F 2025F 2027F 8
Slide 9: 1. Elevate Own-Brand
1. ELEVATE OWN-BRAND Marketing Excellence Expanding Distribution Channels 1 Sales Breakdown by Channel Unit: Million Baht Enhancing Out of Home Media Target 102 Revenue 85 24 Other Remaining from TV 79 Channels Revenue Home 70 14 40% Shopping 15 60% 55 11 40 2 32 23 78 Revenue 71 Increasing Awarenes
Slide 10: 1. Elevate Own-Brand
1. ELEVATE OWN-BRAND Continuous R&D with New Product Launches Black Sesame Oil + 4 Mix Oil BSRB COMPLEX Rice Bran Oil ➢ Nourishes the brain, balance ➢ Nourishes joints and the Nourishes body, bone health, the body, reduce joint pain, nervous system and brain support and rejuvenate skin cells ➢ Suppl
Slide 11: 2. Growing OEM and Beyond
2. GROWING OEM AND BEYOND Thailand OTC Pharmaceutical Market Breakdown Focus on Strategic Products Unit: Billion Baht 2024-26F 1 Large Market 2 High Demand CAGR Pharmaceuticals 48.6 45.8 43.1 40.5 Vitamins & +5.1% 38.6 31% Minerals 32% Cough & Cold Contraceptive Skin 32% Remedies Pills Treatment 32%
Slide 12: 3. Capture Opportunity Through Investment
3. CAPTURE OPPORTUNITY THROUGH INVESTMENT Collaborate with Public Sector 1 Collaborate with to provide free contraceptives via machine Operates a 24- Hour Medicine 2 Grow with Telemedicine ➢ Using the 30 Baht Healthcare Scheme Dispenser Platform through an automated medicine dispenser system ✓ Home
Slide 13: 4. Business Expansion Along the Value Chain
4. BUSINESS EXPANSION ALONG THE VALUE CHAIN: Grace Water 1 2 3 4 5 Med Hemodialysis Hemodialysis Kidney Care RO Plant for Hemodialysis Solution Machine Product Dialysis Clinic Kidney ( In s t al l at io n /R en tal ) ( T r adi n g) ( In s t al l at io n /R en tal ) ( Fut ur e pl an ) Patients Target
Slide 14: Agenda
AGENDA COMPANY OVERVIEW & STRATEGY KEY FINANCIAL PERFORMANCE 2025 OUTLOOK 14
Slide 15: YE 2024 Financial Performance Highlights
YE 2024 Financial Performance Highlights Operating Revenue Financial Summary (YoY) 824.5 MB Unit: Million Baht, % +43.2% 43.2% YoY YoY 824.5 GPM and NPM YE/2024 YE/2024 575.6 37.0% (3.9%) +112.5% 12.1% YoY 8.1% YoY YoY +9,971.6% 305.0 YoY (221.1%) YoY 143.5 ROA and ROE 105.0 27.4 (2.5%) 0.5% Operati
Slide 16: Revenue Breakdown by Business
Revenue Breakdown by Business Overall Revenue Breakdown Million Baht, % +43.2% YoY 824.5 Trading and 5% Others 17% Hemodialysis +51.9% 575.6 YoY 5% Own-Brand +5.3% 12% 41% QoQ 5% 33% 228.7 240.7 6% 5% 158.5 17% 18% 5% 37% OEM 17% 37% 42% 50% 34% 44% 40% 35% Q4/2023 Q3/2024 Q4/2024 YE/2023 YE/2024 Yo
Slide 17: Revenue Breakdown by Product Line
Revenue Breakdown by Product Line Overall Revenue Breakdown Million Baht, % +43.2% YoY 824.5 7% Others 3% Herbal +51.9% YoY 17% Hemodialysis 575.6 +5.3% 7% QoQ 2% 22% 11% Pharmaceutical 32% 228.7 240.7 7% 7% 158.5 1% 2% 51% 6% 17% 18% Supplement 3% 17% 30% 19% 48% 29% 45% 54% 45% Q4/2023 Q3/2024 Q4/
Slide 18: Gross Profit
Gross Profit Gross Profit and Gross Profit Margin Million Baht, % 39.7% 41.6% 37.0% 28.5% 24.9% Overall GPM +112.5% +121.6% YoY YoY +10.2% 305.0 QoQ Gross Profit 143.5 90.8 100.1 45.2 Q4/2023 Q3/2024 Q4/2024 YE/2023 YE/2024 +121.6% +10.2% YoY: Q4/2024 vs Q4/2023 QoQ: Q4/2024 vs Q3/2024 YoY: YE/2024
Slide 19: SG&A
SG&A SG&A AND SG&A TO REVENUE Million Baht, % 27.5% 24.0% 28.6% 25.3% 26.2% SG&A to Total Revenue +35.5 % +51.6% YoY YoY 221.4 +21.7% SG&A Expenses QoQ 163.4 43% Selling Expenses 31% 70.5 46.5 57.9 Administrative 48% 69% 57% Expenses 31% 44% 69% 56% 52% Q4/2023 Q3/2024 Q4/2024 YE/2023 YE/2024 YoY: Q
Slide 20: Profitability: Operating Profit
Profitability: Operating Profit JSP Displayed Outstanding Operating Profits in 2024, however Impacted by a One-time Impairment Item Resulting in a Negative Net Profit Operating Profit Million Baht, % +9,971.6% YoY Operating Profit Impairment to Net Profit +282.1% YoY 105.0 -23.8% QoQ Impairment CDIP
Slide 21: Profitability: Net Profit
Profitability: Net Profit JSP Displayed Outstanding Operating Profits in 2024, however Impacted by a One-time Impairment Item Resulting in a Negative Net Profit Net Profit and Net Profit Margin Million Baht, % 13.1% 2.0% 4.2% -3.9% Net Profit -30.5% Margin -2,297.0% YoY -221.1% -336.8% YoY QoQ 31.7
Slide 22: Statement of Financial Position
Statement of Financial Position Assets Liabilities & Shareholder’s Equity Million Baht, % -0.8% Million Baht, % -0.8% YoY YoY 1,337.4 1,326.7 1,337.4 1,326.7 18% 194.8 14% 228.5 17% Current Current Assets 245.6 Liabilities 313.7 24% 210.8 16% 215.7 16% Non-current Liabilities Non-current 1,091.8 82%
Slide 23: Key Financial Ratios
Key Financial Ratios Current Ratio D/E Ratio Debt Service Coverage Ratio* Times Times Times 1.54 1.37 0.51 1.42 0.50 1.25 0.44 1.30 1.26 Q4/2023 Q3/2024 Q4/2024 Q4/2023 Q3/2024 Q4/2024 Q4/2023 Q3/2024 Q4/2024 ROE* ROA* % % 6.57% 3.88% 1.16% 1.67% -2.50% 0.50% Q4/2023 Q3/2024 Q4/2024 Q4/2023 Q3/2024
Slide 24: Agenda
AGENDA COMPANY OVERVIEW & STRATEGY KEY FINANCIAL PERFORMANCE 2025 OUTLOOK 24
Slide 25: 2025 Outlook
2025 OUTLOOK OEM/ Trading Own-Brand Acquiring Top Brands in Strong contribution from Thailand “Suphap-Osot” Continue to support market ✓ Continuously growing Hero leaders and seek for new Product established players in the ✓ Seeking for new products market ✓ Increasing distribution channels (e.g. On
Slide 26: Thank You
THANK YOU Please scan to give us your feedback IR Contact Tel: 064 479 1691 Email: contact@jsppharma.com
JSP Pharmaceutical Manufacturing (Thailand) Public Company — FY2024 Earnings Presentation on 6ix